Abbott Laboratories (NYSE:ABT) Shares Acquired by CFO4Life Group LLC

CFO4Life Group LLC lifted its position in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 11.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,528 shares of the healthcare product maker’s stock after buying an additional 266 shares during the period. CFO4Life Group LLC’s holdings in Abbott Laboratories were worth $356,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ABT. Capital Investment Advisors LLC increased its holdings in Abbott Laboratories by 4.2% in the 4th quarter. Capital Investment Advisors LLC now owns 13,335 shares of the healthcare product maker’s stock valued at $1,877,000 after purchasing an additional 534 shares in the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in shares of Abbott Laboratories by 4.6% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 110,726 shares of the healthcare product maker’s stock valued at $13,080,000 after acquiring an additional 4,890 shares in the last quarter. Minot Wealth Management LLC grew its stake in shares of Abbott Laboratories by 3.8% during the fourth quarter. Minot Wealth Management LLC now owns 58,450 shares of the healthcare product maker’s stock valued at $8,226,000 after acquiring an additional 2,147 shares in the last quarter. Gradient Investments LLC grew its stake in shares of Abbott Laboratories by 6.2% during the fourth quarter. Gradient Investments LLC now owns 71,707 shares of the healthcare product maker’s stock valued at $10,092,000 after acquiring an additional 4,160 shares in the last quarter. Finally, TRH Financial LLC grew its stake in shares of Abbott Laboratories by 17.4% during the fourth quarter. TRH Financial LLC now owns 59,726 shares of the healthcare product maker’s stock valued at $8,406,000 after acquiring an additional 8,849 shares in the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

In other Abbott Laboratories news, Director Daniel J. Starks sold 50,000 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $113.22, for a total value of $5,661,000.00. Following the transaction, the director now owns 6,973,500 shares in the company, valued at $789,539,670. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Julie L. Tyler sold 462 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $119.29, for a total transaction of $55,111.98. The disclosure for this sale can be found here. Insiders have sold 81,896 shares of company stock worth $9,299,454 in the last quarter. Company insiders own 0.52% of the company’s stock.

Shares of ABT traded up $2.16 during mid-day trading on Thursday, reaching $108.00. 332,451 shares of the company’s stock traded hands, compared to its average volume of 5,971,248. The business’s 50-day moving average price is $117.82 and its 200-day moving average price is $125.01. The stock has a market capitalization of $189.10 billion, a P/E ratio of 24.70, a price-to-earnings-growth ratio of 2.98 and a beta of 0.73. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.46 and a current ratio of 1.85. Abbott Laboratories has a 12 month low of $105.36 and a 12 month high of $142.60.

Abbott Laboratories (NYSE:ABTGet Rating) last released its quarterly earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.26. The company had revenue of $11.90 billion for the quarter, compared to analysts’ expectations of $11 billion. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 earnings per share. Equities research analysts anticipate that Abbott Laboratories will post 4.82 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 16th. Investors of record on Friday, April 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, April 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.74%. Abbott Laboratories’s dividend payout ratio is presently 43.62%.

ABT has been the subject of several recent analyst reports. Morgan Stanley lowered their target price on Abbott Laboratories from $157.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, January 27th. Bank of America initiated coverage on shares of Abbott Laboratories in a research report on Tuesday, March 1st. They set a “buy” rating and a $140.00 price target on the stock. Raymond James reduced their price target on shares of Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. StockNews.com initiated coverage on shares of Abbott Laboratories in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Finally, Royal Bank of Canada reduced their price target on shares of Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $138.83.

Abbott Laboratories Company Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.